GlassScriptPhysician profile
Bernard Aoueille, III
NPI 1285645010
$13,199.85
in general payments reported to CMS, 2019-2025
35 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,270 · 2020: $1,053 · 2021: $3,325 · 2022: $2,599 · 2023: $2,181 · 2024: $1,610 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,952 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,951.78 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,067.67 | 2019-2024 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $1,356.49 | 2021-2024 | Vraylar |
| Alkermes, INC. | $1,258.76 | 2019-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $1,042.52 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $941.86 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $906.33 | 2019-2024 | Trintellix |
| Bausch Health US, LLC | $815.32 | 2019-2024 | Aplenzin, Wellbutrin |
| Allergan, INC. | $471.46 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $453.10 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $442.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $383.75 | 2019-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $377.06 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $362.23 | 2019-2024 | Ingrezza |
| Eisai INC. | $332.98 | 2020-2022 | |
| Axsome Therapeutics, INC. | $283.74 | 2022-2024 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $231.86 | 2019-2024 | |
| Corium, LLC | $179.33 | 2022-2024 | Azstarys |
| Adlon Therapeutics L.P. | $170.24 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $137.93 | 2019-2024 | Austedo Xr, Austedo |
| Shire North American Group INC | $137.92 | 2019 | |
| Supernus Pharmaceuticals, INC. | $123.26 | 2021-2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $118.56 | 2019-2021 | |
| Lilly USA, LLC | $94.00 | 2025 | Zepbound |
| Idorsia Pharmaceuticals US INC | $83.42 | 2023-2024 | Quviviq |
| Upsher-Smith Laboratories LLC | $78.35 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $69.10 | 2019-2020 | |
| Neos Therapeutics, LP | $67.71 | 2019-2021 | |
| Noven Therapeutics, LLC | $40.29 | 2024 | Xelstrym, Secuado |
| Tris Pharma INC | $34.71 | 2019 | |
| Alfasigma USA, INC. | $33.45 | 2022 | |
| Validus Pharmaceuticals LLC | $28.81 | 2019 | |
| Owp Pharmaceuticals, INC. | $28.57 | 2020-2022 | |
| Noven Pharmaceuticals, INC. | $17.43 | 2023 | Xelstrym |
| Azurity Pharmaceuticals, INC. | $16.97 | 2023 | Horizant |
| Merck Sharp & Dohme LLC | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Aoueille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.